Obexelimab
- CAS No.
- 1690307-05-1
- Chemical Name:
- Obexelimab
- Synonyms
- Obexelimab;Obexelimab (anti-CD19);Research Grade Obexelimab
- CBNumber:
- CB08080918
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | RM16A4BA8R |
Obexelimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0629183 | Obexelimab 99.99% | 1690307-05-1 | 1mg | $433 | 2026-06-04 | Buy |
| ChemScene | CS-0629183 | Obexelimab 99.99% | 1690307-05-1 | 5mg | $1300 | 2026-06-04 | Buy |
| ChemScene | CS-0629183 | Obexelimab 99.99% | 1690307-05-1 | 10mg | $2058 | 2026-06-04 | Buy |
| aablocks | AA02DJLR | Obexelimab ≥95%(SDS-PAGE&SEC-HPLC) | 1690307-05-1 | 1mg | $664 | 2026-06-03 | Buy |
| aablocks | AA02DJLR | Obexelimab ≥95%(SDS-PAGE&SEC-HPLC) | 1690307-05-1 | 5mg | $2000 | 2026-06-03 | Buy |
Obexelimab Chemical Properties, Uses, Production
Uses
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus[1][2][3].
in vivo
Obexelimab (10 mg/kg; twice a week; i.p.) can inhibit the autoimmune response of immune deficient mice implanted with peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis (RA) patients[2].
| Animal Model: | Female C.B-17 SCID mice transplanted with PBMCs[2]. |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection (i.p.); twice a week |
| Result: | Resulted in inhibition of various immune responses in mice, including IgG, IgM, RF, ACPA, and anti-tetanus antibodies. |
References
[1] Boyles JS, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023 Jul 10;8(13):e166137. DOI:10.1172/jci.insight.166137
[2] Chu SY, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May;66(5):1153-64. DOI:10.1002/art.38334
[3] Horton HM, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1;186(7):4223-33. DOI:10.4049/jimmunol.1003412
Obexelimab Preparation Products And Raw materials
Raw materials
Preparation Products
Obexelimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
